OncoMatch/Clinical Trials/NCT06851663

Trop2-targeted immunoPET Imaging of Solid Tumors

Is NCT06851663 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including [68Ga]Ga-NOTA-T4 and [68Ga]Ga-NOTA-RT4 for solid tumor.

Treatment: [68Ga]Ga-NOTA-T4 · [68Ga]Ga-NOTA-RT4 · [18F]F-RESCA-T4 · [18F]F-RESCA-RT4 — This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.